NEW YORK, Jan 4, 2026, 10:59 ET — Market closed
- Liquidia (LQDA) last closed at $31.40 after a sharp Friday drop.
- Options screens flagged heavy put volume, including a large Jan. 16 $30/$15 put spread.
- Traders are watching the $30 area and the Jan. 16 options expiry as the next near-term marker.
Liquidia Corporation shares slid in the last U.S. session as options traders piled into downside protection, putting the biotech stock on watch ahead of Monday’s reopen.
The move matters because the options market often telegraphs how investors are positioning for near-term swings, especially in event-driven healthcare names where single headlines can shift the outlook.
Put options — contracts that give the holder the right to sell shares at a set price — can be used to hedge existing stock positions or to bet on a decline. Heavy put demand can also amplify day-to-day moves as dealers adjust hedges.
Liquidia last traded at $31.40, down $3.13, or about 9.1%, on Friday. The stock ranged from $30.76 to $34.97 during the session, after opening near $34.54, with about 2.9 million shares changing hands.
In a daily options market note, Charles Schwab strategist Joe Mazzola flagged “unusual put activity” in Liquidia, estimating more than 15,892 put contracts traded — about five times average daily put volume — and said over a third of that flow came from a January 16, 2026, put vertical spread tied to the $30 and $15 strikes. “The 30.00 strike appears to be a new long position … suggesting bearish intent,” Mazzola wrote. Schwab Brokerage
A separate options roundup published on Nasdaq.com said overall option volume in Liquidia reached 21,762 contracts by mid-afternoon Friday, and highlighted particularly heavy trading in the $30 strike put expiring Jan. 16, with 5,976 contracts.
A put vertical spread typically involves buying one put and selling another put at a lower strike in the same expiration. It can express a bearish view while limiting both the maximum profit and the upfront cost, and it is also used as a defined-risk hedge.
With Friday’s low just above $30 and options activity clustered around that strike, traders are likely to treat $30 as a near-term line. A break below it can force fresh hedging and stop-loss selling, while a hold can invite short-covering after the sharp drop.
But options flow is not a clean read on direction: spreads can be defensive hedges, and positions can flip quickly into expiration week. The larger downside risk for Liquidia remains legal, not technical — the company has disclosed ongoing litigation with United Therapeutics and warned that adverse outcomes could lead to injunctive relief, including the possibility that YUTREPIA could be removed from the market or have its PH-ILD label narrowed; Liquidia also said a court decision is pending following a June 2025 trial in one case.
Macro risk appetite is also back in focus next week. The U.S. Employment Situation report for December 2025 is scheduled for Friday, Jan. 9, at 8:30 a.m. ET, a release that can move rates and broadly reprice higher-volatility growth stocks.
Liquidia has not posted a confirmed date for its next earnings report on its own disclosures, and third-party calendars vary. MarketBeat’s earnings calendar currently lists a March 18, 2026, release as an estimate, which would be the next major checkpoint for updates on commercialization and the litigation backdrop.
